Acute Lymphoblastic Leukemia
Study raises questions about value of high-dose methotrexate for young patients with ALL
NEW ORLEANS — A shorter initial course of higher-dose dexamethasone failed to reduce toxicity vs. the standard regimen among children and young adults with acute lymphoblastic leukemia and lymphoblastic lymphoma, according to study results.
Trial of ponatinib regimen for ALL subset meets primary endpoint
The addition of ponatinib to chemotherapy increased the minimal residual disease-negative complete remission rate for certain adults with acute lymphoblastic leukemia, according to the agent’s manufacturer.
CAR-T destined for earlier lines of therapy in blood cancers, experts say
Despite data on the approach still being accumulated, a panel of experts at Chemotherapy Foundation Symposium predicted that chimeric antigen receptor T cells will become front-line therapy for multiple hematologic malignancies.
CAR-T effective for younger patients with leukemia, regardless of socioeconomic status
Socioeconomic status had no impact on complete remission rates or overall survival among younger patients who received chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia, study results showed.
CAR-T regimen ‘should be new standard’ for high-risk B-cell acute lymphoblastic leukemia
Dual administration of CD19- and CD22-directed chimeric antigen receptor T cells conferred a 99% complete remission rate in younger patients with relapsed or high-risk B-cell acute lymphoblastic leukemia, phase 2 study results showed.
Higher CAR T-cell dose linked to improved outcomes for younger patients with leukemia
Younger patients who received higher doses of tisagenlecleucel for advanced B-cell acute lymphoblastic leukemia achieved better outcomes, according to results of a retrospective study.
FDA grants fast track, rare pediatric disease designations to WU-CART-007 for T-cell ALL
Antibiotic use, certain gut bacteria affect CAR-T efficacy, toxicity
The use of broad-spectrum antibiotics in the month leading up to chimeric antigen receptor T-cell therapy led to poorer outcomes and increased treatment-related toxicities, study results showed.
Daratumumab improves response among younger patients with acute lymphoblastic leukemia
CHICAGO — The addition of daratumumab to chemotherapy improved outcomes among younger patients with relapsed or refractory T-cell acute lymphoblastic leukemia, study results showed.
Rapid manufacturing process allows CAR T cells to be produced in less than a day
One of the major complaints of clinicians who treat patients with chimeric antigen receptor T-cell therapies is the time required to produce the highly individualized treatment.